Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1213 ARTÍCULOS , VIENDO DEL 106 AL 120

From the editor

Garner JD.

J Women Aging. 2014;26(1):1-2. doi: 10.1080/08952841.2013.815562.

Phytoestrogens and cognitive function: a review

Soni M, Rahardjo TB, Soekardi R, Sulistyowati Y, Lestariningsih, Yesufu-Udechuku A, Irsan A, Hogervorst E.

Maturitas. 2014 Mar;77(3):209-20. doi: 10.1016/j.maturitas.2013.12.010. Epub 2014 Jan 8.

Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?

Fischer A.

Neuropharmacology. 2014 May;80:95-102. doi: 10.1016/j.neuropharm.2014.01.038. Epub 2014 Jan 31.

Modulation of inflammation in transgenic models of Alzheimer's disease

Birch AM, Katsouri L, Sastre M.

J Neuroinflammation. 2014 Feb 3;11:25. doi: 10.1186/1742-2094-11-25.

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G.

Expert Rev Clin Immunol. 2014 Mar;10(3):405-19. doi: 10.1586/1744666X.2014.883921. Epub 2014 Feb 4.

Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study

Chang YS, Chen HL, Hsu CY, Tang SH, Liu CK.

J Clin Neurophysiol. 2014 Feb;31(1):81-5. doi: 10.1097/01.wnp.0000436899.48243.5e.

Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces

Rosini M, Simoni E, Minarini A, Melchiorre C.

Neurochem Res. 2014 Oct;39(10):1914-23. doi: 10.1007/s11064-014-1250-1. Epub 2014 Feb 4.

Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer's disease

Drolle E, Hane F, Lee B, Leonenko Z.

Drug Metab Rev. 2014 May;46(2):207-23. doi: 10.3109/03602532.2014.882354. Epub 2014 Feb 5.

Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease

O'Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, Kehoe PG, Guyatt G, Molloy DW.

J Alzheimers Dis. 2014;40(3):595-603. doi: 10.3233/JAD-131694.

The emerging role of glutathione in Alzheimer's disease

Saharan S, Mandal PK.

J Alzheimers Dis. 2014;40(3):519-29. doi: 10.3233/JAD-132483.

Reciprocal disruption of neuronal signaling and Aβ production mediated by extrasynaptic NMDA receptors: a downward spiral

Rush T, Buisson A.

Cell Tissue Res. 2014 May;356(2):279-86. doi: 10.1007/s00441-013-1789-1. Epub 2014 Feb 5.

Stem-cell challenges in the treatment of Alzheimer's disease: a long way from bench to bedside

Fan X, Sun D, Tang X, Cai Y, Yin ZQ, Xu H.

Med Res Rev. 2014 Sep;34(5):957-78. doi: 10.1002/med.21309. Epub 2014 Feb 5.

How plausible is a link between HSV-1 infection and Alzheimer's disease?

Agostini S, Clerici M, Mancuso R.

Expert Rev Anti Infect Ther. 2014 Mar;12(3):275-8. doi: 10.1586/14787210.2014.887442. Epub 2014 Feb 6.

Arginine metabolising enzymes as targets against Alzheimers' disease

Whiteley CG.

Neurochem Int. 2014 Feb;67:23-31. doi: 10.1016/j.neuint.2014.01.013. Epub 2014 Feb 4.

Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease

Bennett DA, Yu L, De Jager PL.

Biochem Pharmacol. 2014 Apr 15;88(4):617-30. doi: 10.1016/j.bcp.2014.01.037. Epub 2014 Feb 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias